REVIEW article
Front. Clin. Diabetes Healthc.
Sec. Diabetes Therapies
Volume 6 - 2025 | doi: 10.3389/fcdhc.2025.1590530
"Exploring the Multifaceted Roles of GLP-1 Receptor Agonists; A Comprehensive
Provisionally accepted
Bisma Fatima Hammad1
Nimrah Zafar2Muneeb Ullah3
Syeda Jazilah Faisal2
Fizzah Iftikhar4Haadia Waheed5Muhammad Waleed Muzaffar6Khadija Ahmed2Faz Ashraf7
Komal Zahid8Maimoona Akhtar4
Mohammed Mahmmoud Fadelallah Eljack9*- 1Liaquat National Medical College, Karachi, Sindh, Pakistan
- 2Dow Medical College, Dow University of Health Sciences, Karachi, Punjab, Pakistan
- 3Saidu Medical College, Swat, Pakistan
- 4Karachi Medical and Dental College, Karachi, Sindh, Pakistan
- 5Dow International Medical College, Dow University of Health Sciences, Karachi, Punjab, Pakistan
- 6Niazi Medical and Dental College, Sargodha, Punjab, Pakistan
- 7Rashid Latif Medical College, Lahore, Punjab, Pakistan
- 8Women Medical and Dental College, Abbottabad, Abbottabad, Khyber Pakhtunkhwa, Pakistan
- 9University of Bakht Alruda, Eldueim, Sudan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Traditionally, Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), a pivotal class of drug, mimics the actions of endogenous Glucagon-like peptide-1, which have been found to be remarkable in the treatment of type 2 diabetes alongside other comorbidities. GLP-1 receptors being widely available in the different organs and tissues such as the brain, lung, pancreas, stomach, heart, and endometrium has explained the broader therapeutic application of GLP-1RA. The recent studies have explored the physiological effects of GLP-1RA on body organs, establishing them as a potential therapeutic option for a wide range of diseases. Activation of GLP-1 receptors contribute to regulation of blood glucose levels, weight management, cardiovascular health, and potential neuroprotection, while also having a positive influence on musculoskeletal health. This review has emphasized the expanded role of GLP-1RA by highlighting the most significant and notable studies. While GLP-1RA has proven clinical efficacy, the need for more comprehensive studies, to ensure their long-term safety, is essential to optimize their therapeutic role and improve patient outcomes on a global scale. Addressing the significant gap for research on cost effectiveness of these drugs is also crucial for their accessibility in comparison to other drugs. Nevertheless, the limited data available calls for a platform for future research to carry out the expanded therapeutic effects of GLP-1RA.
Keywords: Glucagon-like peptide-1, type 2 diabetes, Endothelial Function, Obesity, metabolic syndrome
Received: 09 Mar 2025; Accepted: 18 Jun 2025.
Copyright: © 2025 Hammad, Zafar, Ullah, Faisal, Iftikhar, Waheed, Muzaffar, Ahmed, Ashraf, Zahid, Akhtar and Mahmmoud Fadelallah Eljack. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mohammed Mahmmoud Fadelallah Eljack, University of Bakht Alruda, Eldueim, Sudan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.